

Supplemental Table S1. Clinical Characteristics of Four Groups according to Oral Hypoglycemic Agent Usage

Characteristic	Group 1	Group 2	Group 3	Group 4
Use of AGI or DPP4i	Yes	No	Yes	No
Use of SU	No	No	Yes	Yes
Number	27 (11.4)	59 (25.0)	12 (5.1)	111 (47.0)
Age, yr	61.48±1.2	56.12±1.33	60.75±2.68	58.5±0.76
Male sex	16 (59.3)	39 (66.1)	6 (50.0)	146 (69.9)
Duration of diabetes, yr	7.75±0.96	3.66±0.66	10.31±1.64	9.67±0.66
Body mass index, kg/m ²	25.24±0.61	25.97±0.37	25.83±1.34	26.37±0.31
HbA1c, %	6.81±0.13	6.8±0.12	7.2±0.19	7.18±0.08
Use of MET or TZD	27 (100)	43 (73)	9 (75)	109 (98)

Values are expressed as number (%) or mean ± standard error.

AGI, α -glucosidase inhibitor; DPP4i, dipeptidyl peptidase-4 inhibitor; SU, sulfonylurea; HbA1c, glycated hemoglobin; MET, metformin; TZD, thiazolidinedione.